**Staphylococcus aureus and S. epidermidis in biological systems of hospital environment: Antibiotic resistance patterns in regions of Ukraine**

A. V. Berezhna*, V. O. Tertyshnyi**, V. I. Makarova*, T. O. Chumachenko*

*Kharkiv National Medical University, Kharkiv, Ukraine
**SI Poltava Oblast Laboratory Center of the MoH of Ukraine, Poltava, Ukraine

Article info
Received 19.02.2021
Received in revised form 10.03.2021
Accepted 11.03.2021

Introduction

Bacteria of the *Staphylococcus* genus, especially *S. aureus* are among most frequently encountered infectious agents associated with rendering medical aid (Canadian Nosocomial Infection Surveillance Program, 2020; Voidazon et al., 2020). This is partially due to the fact that staphylococci colonize the mucous membranes and skin of humans. The nose is considered the most frequent localization of *S. aureus* (Wertheim et al., 2005; Brown et al., 2014). Extranasal localizations of *S. aureus* include the skin, crotch area, armpits, and the gastrointestinal tract. It should be noted that a nasal *S. aureus* carrier is prone to be a source of extranasal transmission. For instance, 90% of *S. aureus* nasal carriers usually have the skin on their hands contaminated as well (Wertheim et al., 2005). Another potentially dangerous hospital infection pathogen is *S. epidermidis*. Microorganisms of this genus are referred to resident microflora of the human external surface and are usually normal representatives of the microbiocenosis of every healthy person’s skin, which is also a significant link in the pathogenesis of infections associated with rendering of medical aid (Hellmark et al., 2013). Previously published researches point to the existing problem of incidence of methicillin-resistant genotypes of *S. aureus* and *S. epidermidis* in healthcare workers at hospitals (Du et al., 2013; Widerström et al., 2016; Sharma et al., 2019). In cases of violation of aseptic and antisepsic rules and improper observance of hand hygiene, microorganisms that are on medical personnel’s skin are transmitted to patients, medical devices, equipment, and other objects of the medical environment. When invasive manipulations like catheterization of vessels are conducted, microorganisms may pass from medical personnel’s hands to the surface of a vessel catheter and be the cause of development of catheter-related bloodstream infections (Cherifi et al., 2014).

It is general knowledge that patients in hospitals have at least one peripheral intravenous catheter installed in 30% to 80% of cases (Zhang et al., 2016; Aghdassi et al., 2019). The patients, who need a transfusion of massive amounts of liquid, total parenteral feeding, hemodialysis, or for other reasons, have central venous catheters installed (Smith & Nolan, 2013). Considering the broad application of vessel appliances (including peripheral intravenous catheters) in medical practice, infectious complications associated with vessels’ catheterization account for a large share of infections associated with health care provision. The incidence of blood-
stream infections connected with application of peripheral intravenous catheters varies from 0.0% to 2.2%, amounting on average to 0.18%, with the incidence of nosocomial catheter-related bloodstream infections due to peripheral venous catheters reaching 6.2% to 60.0% (Merrem, 2017). In the etiological structure of infection complications associated with peripheral and central veins catheterization, the S. aureus strains and coagulase-negative staphylococci, including S. epidermidis, prevail (Zhang et al., 2016; Guenbe et al., 2017; Nguyen et al., 2017; Mandolfo et al., 2019; Tatsumo et al., 2019).

Due to the ability of staphylococci to produce biofilms, the infections caused by them are more difficult to treat and may develop into chronic forms. The biofilm forms of bacteria possess a considerably higher resistance to antibiotics than the plankton forms (Wu et al., 2003; Costerton et al., 2005; Kaplan, 2011). S. aureus strains producing biofilms possess a higher resistance level to most medications, which is prognostically an unfavourable factor in such patients' treatment (Manandhar et al., 2018).

Under conditions of growth in microorganism resistance to medications, of grave concern are bacteremia cases caused by antibiotic-resistant strains of S. aureus and S. epidermidis. It is established that bacteremia caused by methicillin-resistant strains of S. aureus is more often associated with health care provision, in particular with application of central venous catheters. In such cases, apart from considerable economic losses, the life prognosis for patients is unfavourable. The mortality in a 28-day-period from methicillin-resistant S. aureus bacteria is 1.6 times higher than from bacteremia caused by S. aureus strains producing penicillinase (Jokinen et al., 2017).

Identifying microorganism resistance and determining the mechanisms influencing their resistance to antibiotics and their ability to produce biofilm forms, as well as an increase in their virulence and pathogenicity, should be one of priority directions in the healthcare system of any state. Due to staphylococci’s (especially S. aureus) possessing a high degree of adaptability and genomic variability (Deurenberg et al., 2007; Deurenberg & Stobberingh, 2008; Lindsay, 2010; Conlan et al., 2012), it is necessary to maintain a permanent monitoring of their resistance.

In 2018, the results of a wide-scale multicentered epidemiology research project on determining antibiotic-resistance (Survey of Antibiotic Resistance, SOAR) concerning Ukraine and Slovakia were published. On the example of non-hospital respiratory infections agents Streptococcus pneumoniae and Haemophilus influenzae, territorial differences in the resistance level of the located isolates in the two neighbouring countries were found (Torumkuney et al., 2018). Overall, other studies on microorganism resistance to antibiotics, currently conducted in Ukraine, are narrowly specialized and do not encompass the problem in general.

It should be noted that there are differences in antibacterial resistance in organisms circulating in different departments of the same healthcare setting. For instance, the strains found in intensive care patients are often more resistant and may possess multiple resistance to antibiotics (Kollef & Stobberingh, 2008; Lindsay, 2010; Conlan et al., 2012). It was also noted that in the countries with lower income levels, the burden of antibiotic resistance in intensive care units is much heavier than in the countries with high incomes (Saharman et al., 2021). Everything mentioned above points to the expediency of estimating territorial differences in staphylococci antibiotic resistance in the regions of Ukraine. Therefore, the goal of this study is to perform a comparative analysis of antibiotic resistance in S. aureus and S. epidermidis isolates identified in surgical hospitals of two neighbouring areas: the Kharkiv and the Poltava regions.

### Materials and methods

The study included clinical specimens collected from surgical patients by bacteriological laboratories in health-care settings of Kharkiv and Poltava regions in 2013–2019. S. aureus and S. epidermidis strains were isolated and identified according to standard methods. Antibacterial resistance in staphylococci was determined using the disc-diffusion method on Mueller-Hinton agar according to Clinical and Laboratory Standards Institute Guidelines (Bauer et al., 1966; Clinical Laboratory Standards Institute, 2014). In total, 151,015 and 98,754 tests to determine antibacterial resistance of S. aureus in Kharkiv and Poltava regions respectively were carried out in 2013–2019 and 15,589 tests to determine antibiotic resistance in S. epidermidis strains in Kharkiv region were carried out in 2013–2015 (Table 1).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kharkiv region</td>
<td>Poltava region</td>
</tr>
<tr>
<td>Penicillins</td>
<td>28,904</td>
<td>15,676</td>
</tr>
<tr>
<td>Cephalosporins</td>
<td>17,159</td>
<td>5,340</td>
</tr>
<tr>
<td>Carboxypenicillins</td>
<td>5,202</td>
<td>3,018</td>
</tr>
<tr>
<td>Aztreomycin</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td>21,144</td>
<td>10,762</td>
</tr>
<tr>
<td>Macrolides</td>
<td>7,642</td>
<td>10,092</td>
</tr>
<tr>
<td>Lincomycin</td>
<td>10,156</td>
<td>8,792</td>
</tr>
<tr>
<td>Tetracyclines</td>
<td>3,534</td>
<td>9,934</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>7,870</td>
<td>7,120</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>5,606</td>
<td>908</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>33,619</td>
<td>15,771</td>
</tr>
<tr>
<td>Linzolid</td>
<td>11,210</td>
<td>8,097</td>
</tr>
<tr>
<td>Co-trimoxazole</td>
<td>14</td>
<td>1,025</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>755</td>
<td>1,355</td>
</tr>
<tr>
<td>Phosphomycin</td>
<td>0</td>
<td>293</td>
</tr>
<tr>
<td>Fusid acid</td>
<td>0</td>
<td>220</td>
</tr>
<tr>
<td>Nitrofuran derivatives</td>
<td>0</td>
<td>331</td>
</tr>
<tr>
<td>Total</td>
<td>151,015</td>
<td>98,754</td>
</tr>
</tbody>
</table>

For assessment of the resistance of S. aureus strains, the tested antibiotics included penicillins (penicillin, benzylpenicillin, ampicillin, amoxicillin, oxacillin, ampicillin, amoxicillin/sulbactam, amoxicillin/clavulanic acid), cephalosporins (cefazolin, cefalotin, cephalexin, cefuroxime, cefoperazone, cefotaxime, ceftriaxone, cefaluzidine, cefepime, cefpirom, cefoperazone/sulbactam), carbapenems (imipenem, meropenem, imipenem/cilastatin), aminoglycosides (kanamycin, gentamicin, tobramycin, netilmicyn, amikacin), macrolides (erythromycin, clarithromycin, azithromycin, spiramycin), linezolid (clindamycin, lincomycin), tetracyclines (tetracycline, doxycycline, tigecycline), glycopeptides (vancomycin), an antituberculosis medicine rifampicin, fluoroquinolones (ciprofloxacin, ofloxacin, cefoxolin, norfloxacin, lomefloxacin, levofloxacin, moxifloxacin, gatifloxacin), oxazolidinones (linezolid), sulfanilamides (co-trimoxazole), amphenicols (chloramphenicol) and others (phosphorycin, fusidic acid, nitrofuran derivatives).

Depending on the year and the region, the study to estimate resistance in the S. aureus strains had its peculiarities. In particular, in 2013, 2014, 2018, 2019, no tests were made in Poltava region to estimate resistance to cephalosporin group antibiotics and carbapenems in S. aureus isolates. In 2013, 2014, 2018, 2019, resistance in S. aureus isolates was studied in relation to only one antibiotic of the aminoglycoside group, gentamicin, and to only one antibiotic of the macrolide group, erythromycin in Poltava region. In 2013 and 2014, the resistance in S. aureus isolates was studied in relation to only one antibiotic of the tetracycline group, tetracycline in Kharkiv region. Resistance in S. aureus isolates to co-trimoxazole in Kharkiv region was assessed only in 2015 and 2018. Resistance of S. aureus isolates to chloramphenicol in Kharkiv region was not assessed in 2013 and 2014. Resistance of S. aureus isolates to phosphomycin, fusidic acid and nitrofuran derivatives was estimated only in Poltava region in (2014, 2015, and 2017 – to phosphomycin; in 2016–2018 – to fusidic acid; in 2015, 2016, and 2018 – to nitrofuran derivatives).

To increase data validity, we calculated the average proportion of S. aureus isolates resistant to antibiotics groups (penicillins, cephalosporins, etc.) rather than to individual medications (with the exception of vancomycin, rifampicin, co-trimoxazole, chloramphenicol, phosphomycin, fusidic acid as the sole representatives of their antibiotic groups).

For estimation of resistance of S. epidermidis strains, the tested antibiotics included penicillins (penicillin, ampicillin, amoxicillin, oxacillin, carbapenem, ampicillin/sulbactam, amoxicillin/clavulanate), cephalosporins (cefazolin, cefalotin, cephalexin, cefaluzidine, cefepime, cefpirom, cefoperazone/sulbactam), carbapenems (imipenem, meropenem), monobactams (aztreomycin), aminoglycosides (kanamycin, gentamicin, tobramycin, netilmicyn, amikacin), macrolides (erythromycin, clarithromycin, azithromycin, spiramycin), linezolid (clindamycin, lincomycin), tetracyclines (tetracycline, doxycycline, tigecycline), glycopeptides (vancomycin), an antituberculosis medicine rifampicin, fluoroquinolones (ciprofloxacin, ofloxacin, cefoxolin, norfloxacin, lomefloxacin, levofloxacin, moxifloxacin, gatifloxacin), oxazolidinones (linezolid), sulfanilamides (co-trimoxazole), amphenicols (chloramphenicol) and others (phosphorycin, fusidic acid, nitrofuran derivatives).
cosides (gentamycin, tobramycin, amikacin), macrolides (erythromycin, clarithromycin, azithromycin), lincozamides (clindamycin, lincomycin), tetracyclines (tetracycline, doxycycline), glycopeptides (vancomycin), an antituberculosis medicine rifampicin, fluoroquinolones (ciprofloxacin, ofloxacin, pefloxacin, norfloxacin, lomefloxacin, levofloxacin), aztreonam (azulozid), sulphanilamides (co-trimoxazol), amphenicols (chloramphenicol). In some years, the resistance of *S. epidermidis* was identified only for one antibiotic within a certain class: in 2013 – for imipenem, (linezolid), sulphanilamides (co-trimoxazol), amphenicols (chloramphenicol).

The largest proportion of *S. aureus* isolates resistant to macrolides in Kharkiv region was identified in 2017 (55.4%), and in Poltava region – in 2019 (42.0%). The smallest proportion of *S. aureus* isolates resistant to macrolides in Kharkiv region was identified in 2013 (6.5%), and in Poltava region – in 2015 (12.5%). It was found that the proportion of *S. aureus* isolates resistant to macrolides in 2013, 2016, and 2019 was statistically significantly higher in Poltava region. In other years (except 2014) statistically significant differences were found to be in favour of a higher resistance of *S. aureus* isolates in Kharkiv region (Fig. 2a). Generally, during the period from 2013 to 2019, the proportion of *S. aureus* isolates resistant to the macrolides group medications was slightly higher (1.1 times) in Kharkiv region (19.9% / n = 1,522 of 7,642 versus 18.1% / n = 1,827 of 10,092; χ² = 9.3; P = 0.002).

In Kharkiv region, the largest proportion of *S. aureus* strains resistant to lincozamids was identified in 2015, and the smallest – in 2013 (41.6% and 3.1% respectively). In Poltava region more than half of the identified *S. aureus* strains in 2014 (54.0%) were resistant to lincozamids group antibiotics. The lowest resistance to lincozamids in Poltava region was in *S. aureus* strains identified in 2015 (10.0%). Statistically significant differences in proportion of *S. aureus* strains resistant to lincozamids in the compared regions were found in 2013–2015 and in 2017–2019 (Fig. 2b). On the whole, during the analyzed period 1.9 times more *S. aureus* isolates resistant to lincozamids were identified in Poltava region than in Kharkiv region (16.3% / n = 1,436 of 8,792 versus 8.5% / n = 864 of 10,156; χ² = 270.6; P < 0.001).

The proportion of *S. aureus* isolates resistant to the tetracycline medications group in Kharkiv region varied within 0.6% in 2013 to 15.3% in 2016. The proportion of tetracycline resistant *S. aureus* strains in Poltava region reached its maximum in 2019, amounting to 30.5%. The smallest proportion of the resistant isolates in Poltava region was identified in 2015 (9.1%). The statistically significant differences between the proportion of tetracycline-resistant *S. aureus* isolates in the compared regions were identified in 2013, 2014, and 2016-2019 (Fig. 2c). On the whole, during the studied period, the proportion of *S. aureus* strains resistant to tetracycline antibiotics was 1.9 times higher in Poltava region (15.7% / n = 1,560 of 9,934 versus 8.3% / n = 294 of 3,534; χ² = 119,7; P < 0.001).

In Kharkiv region in 2013 and 2014, 96.3% and 89.1% isolated *S. aureus* strains respectively were resistant to vancomycin. The smallest amount of *S. aureus* strains resistant to vancomycin in Kharkiv region was identified in 2016 (0.6%). In Poltava region, of the 1063 *S. aureus* isolates studied in 2017, none was resistant to vancomycin. Nevertheless, more than the quarter of the identified isolates in 2019 (26.6%) in Poltava region were resistant to this antibiotic. In 2013, 2014 and 2017, the proportion of *S. aureus* isolates resistant to vancomycin was statistically significantly higher (P < 0.001) in Kharkiv region (Fig. 3a).

Using Fisher’s exact test, we found statistically significant differences in proportion of rifampicin resistant isolates of *S. aureus* in the compared regions in 2013, 2014 and 2016 (P < 0.05). The proportion of rifampicin-resistant isolates of *S. aureus* in the Poltava region was higher. It should be noted that during the whole studied period, the proportion of rifampicin-resistant *S. aureus* isolates in Kharkiv region did not exceed 7.8% (n = 19 of 244 in 2017), and in Poltava region it did not exceed 11.6% (n = 11 of 95 in 2016).

Comparative analysis by the regions of resistance of *S. aureus* isolates to fluoroquinolones medications showed that in Poltava region the proportion of resistant strains prevailed over that of Kharkiv region during the whole period of observation except 2017 (Fig. 3b). In Poltava region, the proportion of the resistant strains varied between 15.6% in 2014 and 24.5% in 2019. In Kharkiv region, the proportion of the resistant isolates was between 3.0% in 2013 and 26.9% in 2017. Overall, during the studied period, the proportion of fluoroquinolone resistant *S. aureus* strains was 3.3 times higher in Poltava region (19.7% / n = 3,110 of 15,771 versus 5.9% / n = 1995 of 33,619; χ² = 2201; P < 0.001).
The analysis of \textit{S. aureus} strains resistant to linezolid has demonstrated that in Poltava region the proportion of resistant microorganisms was statistically significantly higher in 2013–2014 and 2016–2018 (Fig. 3c). Notably, in Kharkiv region linezolid-resistant strains accounted for 19.3% of antibiotic resistant strains identified in 2015, which exceeded by 8.5% the maximum proportion of linezolid-resistant strains of \textit{S. aureus} identified in Poltava region. Due to the small number of co-trimoxazol sensitivity tests (n = 14) of \textit{S. aureus} made in Kharkiv region, it is impossible to interpret correctly the negative results obtained. Nevertheless, more tests were made in Poltava region, and the proportion of resistant isolates varied there between 3.4% (n = 9 of 268) in 2019 and 43.7% (n = 52 of 119) in 2016.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig1.png}
\caption{Proportion (x ± SE, %) of penicillin antibiotics-resistant (a), cephalosporin antibiotics-resistant (b), carbapenem antibiotics-resistant (c), aminoglycoside antibiotics-resistant (d) strains of \textit{S. aureus} in Kharkiv and Poltava regions during 2013–2019: * – the differences are statistically significant at $P < 0.01$, ** – antibiotic resistance was not studied in Poltava region that year, *** – there are available data on resistance to only one aminoglycoside antibiotic (gentamycin).}
\end{figure}
Fig. 2. Proportion (± SE, %) of macrolide antibiotics-resistant (a), lipoxazamid antibiotics-resistant (b), tetracycline antibiotics-resistant (c), strains of *S. aureus* in Kharkiv and Poltava regions during 2013–2019: * – the differences are statistically significant at \( P < 0.01 \), • – the differences are statistically significant at \( P < 0.05 \), ** – there are available data on resistance to only one macrolide antibiotic (erythromycin), *** – there are available data on resistance to only one tetracycline antibiotic (tetracycline)

The largest proportion of *S. aureus* isolates resistant to chloramphenicol was identified in Kharkiv region in 2018 (60.4%), and in Poltava region – in 2014 (63.6%). In 2016–2019, the differences in both regions were statistically significant (Fig. 3d). During the period of 2014–2015 and in 2017, in Poltava region 9.2% (n = 27 of 293) of *S. aureus* isolates were found to be resistant to phosphomycin. 8.2% (n = 18 of 220) of *S. aureus* strains were found to be resistant to fusidic acid in Poltava region in 2016–2018. Also, in 2015–2016 and in 2018 in Poltava region, 41.4% (n = 137 of 331) of *S. aureus* isolates were identified as resistant to nitrofuran derivatives. The analysis of *S. epidermidis* isolates’ resistance has demonstrated that in Kharkiv region in 2015, nearly half (47.6%) of the isolates were found to be resistant to the penicillin antibiotics (Fig. 4).

Notably, from 2012 to 2015 among the *S. epidermidis* isolates there was a growth in the prevalence of resistance to cephalosporins, aminoglycosides, macrolides, and fluoroquinolones. When determining the carbenem-resistant strains in 2013, 3.1% (n = 1 of 32) of *S. epidermidis* were found to be resistant to imipenem. In 2014 and 2015, the proportion of the carbenem-resistant strains was considerably larger, 15.5% (n = 25 of 161) and 16.3% (n = 33 of 203) respectively. In 2013, sensitivity in 11 strains of *S. epidermidis* to aztreonam was determined. In three cases, the isolates were resistant. In 2013 and 2014, relatively few lipoxazamid-resistant isolates were identified: 1.7% (n = 8 of 470) and 5.5% (n = 16 of 289) respectively. In 2015, sensitivity to clindamycin was identified in 13 *S. epidermidis* strains. In four cases, the isolates were resistant. The proportion of tetracycline-resistant isolates in 2013 comprised 4.2% (n = 9 of 213), in 2014 – 4.9% (n = 11 of 223). When analyzing *S. epidermidis* resistance to vancomycin, a decrease in the proportion of resistant strains from 88.0% in 2013 to 8.7% in 2015 was noted. The resistance of *S. epidermidis* isolates to rifampicin was studied only in 2013 and 2014. The proportion of the resistant strains was 3.7% (n = 8 of 214) and 8.7% (n = 2 of 23) respectively. In 2015, the proportion of linezolid-resistant strains grew sharply. In 2015, sensitivity to chloramphenicol was identified in 28 *S. epidermidis* strains. In 24 cases (85.7%), the isolates were resistant.

**Discussion**

The study has confirmed the existence of differences in the prevalence of *S. aureus* isolates resistant to various groups of antibacterial medications in Kharkiv and Poltava regions. In Kharkiv region, strains resistant to medications of penicillin group, cephalosporins, carbenem, aminoglycosides, macrolides, and fluoroquinolones. When determining the carbenem-resistant strains in 2013, 3.1% (n = 1 of 32) of *S. epidermidis* were found to be resistant to imipenem. In 2014 and 2015, the proportion of the carbenem-resistant strains was considerably larger, 15.5% (n = 25 of 161) and 16.3% (n = 33 of 203) respectively. In 2013, sensitivity in 11 strains of *S. epidermidis* to aztreonam was determined. In three cases, the isolates were resistant. In 2013 and 2014, relatively few lipoxazamid-resistant isolates were identified: 1.7% (n = 8 of 470) and 5.5% (n = 16 of 289) respectively. In 2015, sensitivity to clindamycin was identified in 13 *S. epidermidis* strains. In four cases, the isolates were resistant. The proportion of tetracycline-resistant isolates in 2013 comprised 4.2% (n = 9 of 213), in 2014 – 4.9% (n = 11 of 223). When analyzing *S. epidermidis* resistance to vancomycin, a decrease in the proportion of resistant strains from 88.0% in 2013 to 8.7% in 2015 was noted. The resistance of *S. epidermidis* isolates to rifampicin was studied only in 2013 and 2014. The proportion of the resistant strains was 3.7% (n = 8 of 214) and 8.7% (n = 2 of 23) respectively. In 2015, the proportion of linezolid-resistant strains grew sharply. In 2015, sensitivity to chloramphenicol was identified in 28 *S. epidermidis* strains. In 24 cases (85.7%), the isolates were resistant.
glycosides, and macrolides were identified more often than in Poltava region. In Poltava region, strains resistant to linezolid, tetracycline antibiotics, and fluoroquinolones were identified more often than in Kharkiv region. This can be ascribed to the regional peculiarities in antibiotics consumption by the population and in medical practices. A high occurrence of S. aureus isolates resistant to natural and some synthetic and semisynthetic penicillin antibiotics (penicillin, ampicillin) is confirmed by other authors’ studies (Deyno et al., 2017; Yilmaz & Aslantaş, 2017). Inhibitor-protected penicillins still remain quite efficient, although the high adaptability of S. aureus can make antibiotics of this group totally inefficient rather soon.

**Fig. 3.** Proportion (x ± SE, %) of vancomycin-resistant (a), fluoroquinolones-resistant (b), linezolid-resistant (c), chloramphenicol-resistant (d) strains of S. aureus in Kharkiv and Poltava regions during 2013–2019: *— the differences are statistically significant at Р < 0.01, •— the differences are statistically significant at Р < 0.05, **— antibiotic resistance was not studied in Kharkiv region in this year

---

We noted that in Poltava region, the proportion of S. aureus isolates resistant to cephalosporins and carbapenems is relatively low. The monitoring of resistance to these antibiotics groups in Poltava region is not conducted on a regular basis. In Kharkiv region, the largest proportion of strains resistant to cephalosporins and carbapenems medications amounted to 39.9% and 42.0% respectively. Therefore, Poltava region also needs to monitor on a regular basis the resistance of S. aureus to these groups of medications and to apply them in treatment protocols with care.

Linezolid is an antibiotic which is efficient against their data versus 19.3% of resistant strains identified in 2015 in Kharkiv identified a high resistance to linezolid (0% of resistant strains according to gram-positive flora including meticillin-resistant staphylococci (Gu et al., 2017), therefore the results obtained by us in this study call for further study and identifying the causes of such a high resistance.

Similar data (compared with Poltava region) concerning *S. aureus* resistance to co-trimoxazol were demonstrated by Deyno et al. (2017). Due to the insufficient amount of tests in Kharkiv region, we think that it is necessary to continue studying the sensitivity to co-trimoxazol in Kharkiv region to find out whether there are any territorial differences in *S. aureus* resistance to this antibiotic.

When analyzing the dynamics of prevalence of resistant *S. aureus* strains in the regions, we found a broad difference in the proportion of isolates resistant to some antibiotics. For instance, in Kharkiv region, 96.3% of *S. aureus* isolates were found to be vancomycin-resistant in 2013, while in 2016 – less than 1%. Also in Kharkiv region, 3.1% of strains were found to be resistant to the lincomycin group in 2013, while in 2015 – 41.6%. These results can be probably ascribed to the disproportional amount of cultures sampled in healthcare settings for our study. This indicates that every healthcare setting has unique microbiological profile.

The research by Mohaghegh et al. (2015) has demonstrated efficiency in using chloramphenicol against *S. aureus* isolates sampled from the patients with suspected bacteremia. In our study, the proportion of chloramphenicol-resistant isolates was high in both regions in certain years. In view of this, we think that the study of *S. aureus* sensitivity to this medication should be continued by increasing the number of the studied isolates.

As to *S. epidermidis*, it should be noted that despite its long since proven pathogenicity (Morgunov & Kuldarchev, 1986), this microorganism is still underestimated in medical practice as being a cause of a number of infections. At the same time, *S. epidermidis* possesses properties and mechanisms owing to which it manages to fix itself on the human body and avoid being destroyed by the immune system. Normally, owing to its adhesive properties, *S. epidermidis* fixes itself to the host’s proteins in the skin, and in cases of damage, wounds, introduction of foreign bodies (prosthetics, vessels catheterization), the infectious agent fixes itself to deeper-laying tissues or to the surface of the implanted appliances (Sahatçü Bresco et al., 2017).

The analyses on determining *S. epidermidis* strains resistance to antibiotics made in Kharkiv region show in the dynamics a rise in the proportion of isolates resistant to most of the antibiotics groups: to penicillins, cephalosporins, aminoglycosides, macrolides, and fluoroquinolones. As early as in 1980, Archer & Tenenbaum in their study on patients surviving heart operations reported a high proportion of *S. epidermidis* isolates resistant to naphycillin, penicillin (100% each), to cephalotin (93%), to cephamandol (80%), to streptomycin (67%). Other researchers report the high prevalence of resistance in hospital *S. epidermidis* strains to many medications: to penicillin, cephalosporin, tetracycline, erythromycin. Moreover, in the isolated strains simultaneous resistance to more than three groups of antibiotics was observed, and in 17.4% – to seven different groups of antibiotics (Chabi & Momtaz, 2019). Of great concern is the high proportion of vancomycin-resistant *S. epidermidis* strains isolated in Kharkiv region in 2013. Nunes et al. (2016) state that the resistance in *S. epidermidis* strains to glycopeptides antibiotics is influenced by the thickness of the cell’s membrane. Also, the authors report the heteroresistance of *S. epidermidis* to glycopeptides. At the same time, in another study, vancomycin is viewed as the most efficient medicine against *S. epidermidis* for treating patients with suspected bacteremia (Mohaghegh et al., 2015). Chabi & Momtaz (2019) also reported the high prevalence of *S. epidermidis* resistance to co-trimoxazol. Because in the present study we did not identify resistance to this medication, it should be accounted for in further studies. Therefore, considering the aforementioned, the study of resistance of *S. epidermidis* isolates should be obligatory all over the country without limitation to individual regions. Our study demonstrates that in Ukraine there is a need for the introduction of a complex approach to the issue of antibiotic resistance. Epidemiological monitoring of hospital infectious agents should be strengthened at the national level, and in the regions, the scope of conducted bacteriological researches should be broadened with further identification of antibiotic sensitivity in the isolated strains. It is also necessary to identify in the isolated microorganisms the ability to form biofilms and the traits of their biofilm forms. Additional introduction of molecular-genetic methods, identifying heteroresistance in microorganisms and the study of their subpopulations can help the patients whose treatment does not call for further study and identifying the causes of such a high resistance.
The study has been performed within the framework of the science-and-research taskance of bacteria causing healthcare-associated infections in healthcare facilities’ work Epidemiology Department of Kharkiv National Medical University titled ‘Epidemiology of microorganisms and antibiotic resistance in hospital strains of microorganisms, it is necessary to develop new and improve the acting local protocols of patients’ antibiotic treatment. Rational and scientifically substantiated application of antibiotic medications in medical practices will enable efficient prevention of formation of microorganism-resistant strains, which will raise the quality of healthcare and rendered to the population, decrease the number of complications, and diminish economic losses caused by infections associated with resistant microorganisms.

Conclusion

We identified peculiarities in antibiotic resistance patterns in regions of Ukraine. In total, the proportion of Staphylococcus aureus strains resistant to penicillins, cephalosporins, carbapenems, aminoglycosides, and macrolides was higher in Kharkiv region in terms of statistical validity than in Poltava region. Overall, the proportion of Staphylococcus aureus strains resistant to linezolidum, tetracycline antibiotics, and fluoroquinolones in Poltava region was higher in terms of statistical validity than in Kharkiv region. Assessment of antibiotic resistance in Staphylococcus epidermidis isolates in Kharkiv region showed increase in resistance to the most antibiotics (penicillins, cephalosporins, aminoglycosides, macrolides, and fluoroquinolones).

Further studies are needed to create of passporhts of microorganism resistance in the regions and medical institutions, as well as to create a unified national database network on microorganism resistance using modern methodologies of determining the phenotypes and genotypes of microorganisms.

The authors would like to express their sincere gratitude to the SI Khar-

References


therapy, 17(2), 269–272.


ficial Organs, 34(9), 737–751.

Kollef, M., & Fraser, V. (2001). Antibiotic resistance in the intensive care unit. An-

nals of Internal Medicine, 134(4), 298–314.

Lindsay, J. (2010). Genomic variation and evolution of Staphylococcus aureus. In-

ternational Journal of Medical Microbiology, 300(2–3), 98–103.


logy, 9, 2749.

Mandolfo, S., Anisi, A., Maggio, M., Rognoni, V., Galli, F., & Fornesi, G. (2019). High success rate in salvage of catheter-related bloodstream infections due to Staphylococcus aureus, on behalf of project group of Italian society of nephro-


Chahi, R., & Montzut, H. (2019). Virulence factors and antibiotic resistance proper-

ties of the Staphylococcus epidermidis strains isolated from hospital infections in Alvaar, Iran. Tropical Medicine and Health, 47(1), 32–39.


Clinical and Laboratory Standards Institute (2014). Performance standards for anti-

microbial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-S24. Wayne, Pennsylvania.


